Australian biotechnology specialist NeuClone has commenced dosing of its NeuLara (ustekinumab) biosimilar to Janssen’s Stelara, in a Phase I clinical trial. NeuClone said that prior to initiating the trial, “NeuLara was subjected to extensive pre-clinical testing to confirm structural and functional similarity in comparison to the reference product.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?